How much does the patient have to pay out-of-pocket after sunitinib is reimbursed by medical insurance?

Sunitinib is a targeted drug commonly used to treat a variety of cancers, especially in the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). The drug prevents tumor growth and metastasis by targeting and inhibiting tumor angiogenesis. With the launch of sunitinib in the Chinese market, patients not only have access to treatment opportunities, but also receive certain cost reimbursements through medical insurance policies. The brand name of sunitinib's original drug is "Sunitinib Malate Capsules". Under China's medical insurance policy, it has been included in the Class B medical insurance directory, which provides financial support to patients.

The medical insurance reimbursement policy has reduced the burden of treatment for patients, especially the treatment with targeted drugs, which is usually more expensive. For patients who meet the medical insurance reimbursement standards, the cost of sunitinib will be reimbursed by medical insurance on a proportional basis, and the patient will need to pay a certain amount out of pocket. According to the current situation, the common specifications of sunitinib malate capsules are12.5mg*28 capsules/box, and the market price is about RMB 2,000. The proportion of medical insurance reimbursement will vary according to different regions and the level of medical insurance enjoyed by the patient.

When patients choose sunitinib treatment, they should communicate with the hospital's medical insurance department to clarify the reimbursement ratio and co-pay amount they can enjoy. This can help patients better plan their financial expenses during treatment. In general, sunitinib has greatly reduced the financial burden of treatment on patients through the support of medical insurance reimbursement, allowing more patients to benefit from this advanced targeted drug.

With the continuous improvement of medical insurance policies and the popularization of drug treatment, more patients will be able to receive more financial support in the future, thereby enjoying higher-quality treatment and improving their quality of life. During treatment with sunitinib, patients should also undergo regular physical examinations and evaluation of treatment effects to ensure the best effect of the treatment plan.

Reference materials:https://www.sutent.com/